The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence

Giovanni Iolascon, Michele Vitacca, Elena Carraro, Carmelo Chisari, Pietro Fiore, Sonia Messina, Tiziana Enrica Giovanna Mongini, Valeria A Sansone, Antonio Toscano, Gabriele Siciliano, Giovanni Iolascon, Michele Vitacca, Elena Carraro, Carmelo Chisari, Pietro Fiore, Sonia Messina, Tiziana Enrica Giovanna Mongini, Valeria A Sansone, Antonio Toscano, Gabriele Siciliano

Abstract

Late-onset Pompe disease (LOPD) is characterized by progressive muscle weakness, respiratory muscle dysfunction, and minor cardiac involvement. Although in LOPD, as in other neuromuscular diseases, controlled low impact sub-maximal aerobic exercise and functional ability exercise can improve general functioning and quality of life, as well as respiratory rehabilitation, the bulk of evidence on that is weak and guidelines are lacking. To date, there is no specific focus on rehabilitation issues in clinical recommendations for the care of patients with Pompe disease, and standard practice predominantly follows general recommendation guidelines for neuromuscular diseases. The Italian Association of Myology, the Italian Association of Pulmonologists, the Italian Society of Neurorehabilitation, and the Italian Society of Physical Medicine and Rehabilitation, have endorsed a project to formulate recommendations on practical, technical, and, whenever possible, disease-specific guidance on rehabilitation procedures in LOPD, with specific reference to the Italian scenario. In this first paper, we review available evidence on the role of rehabilitation in LOPD patients, particularly addressing the unmet needs in the management of motor and respiratory function for these patients.

Keywords: endurance and resistance training; late-onset Pompe disease; motor function; rehabilitation; respiratory function.

References

    1. Boentert M, Prigent H, Vardi K, et al. Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease. Int J Mol Sci 2016;17:E1735.
    1. Morales JA, Bhimji SS. Glycogen Storage Disease, Type II (Pompe Disease). StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2017.
    1. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-88.
    1. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372:1342-53.
    1. Favejee MM, Huisstede BM, Bussmann JB, et al. Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients. Mol Genet Metab 2012;107:111-5.
    1. Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259:952-8.
    1. de Vries JM, van der Beek NA, Hop WC, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 2012;7:73.
    1. Gungor D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013;8:49.
    1. Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 2017;264:621-30.
    1. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 2013;260:951-9.
    1. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010;362:1396-406.
    1. Slonim AE, Bulone L, Goldberg T, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007;35:70-7.
    1. van den Berg LE, Favejee MM, Wens SC, et al. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis 2015;10:87.
    1. Baldanzi S, Ricci G, Bottari M, et al. The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1. Arch Ital Biol 2017;155:43-53.
    1. Ricci G, Bertolucci F, Logerfo A, et al. A multi-parametric protocol to study exercise intolerance in McArdle’s disease. Acta Myol 2015;34:120-5.
    1. Ricci G, Simoncini C, Baldanzi S, et al. Opportunities and potential applications from healthcare technologies to assist motor activity in metabolic myopathies. Bio Eng Med 2018;3:1-4.
    1. Favejee MM, van den Berg LE, Kruijshaar ME, et al. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning. Arch Phys Med Rehabil 2015;96:817-22.
    1. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-8.
    1. Wasserman K, Hansen JE, Sue DY, et al. Measurements during integrative cardiopulmonary exercise testing. Weinberg R, ed. Principles of exercise testing. Baltimore: Lippincott, Williams and Wilkins; 1999, pp. 62-94.
    1. Crescimanno G, Modica R, Lo Mauro R, et al. Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease. Neuromuscul Disord 2015;25:542-7.
    1. van Capelle CI, van der Beek NA, de Vries JM, et al. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis 2012;35:317-23.
    1. van der Beek NA, Hagemans ML, van der Ploeg AT, et al. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord 2013;23:256-64.
    1. Kuperus E, Kruijshaar ME, Wens SCA, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology 2017;89:2365-73.
    1. Vincent KA, Carr AJ, Walburn J, et al. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051-7.
    1. Sansone VA, Panzeri M, Montanari M, et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol 2010;17:1178-87.
    1. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012;45:319-33.
    1. van den Berg LE, Zandbergen AA, van Capelle CI, et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone 2010;47:643-9.
    1. Bertoldo F, Zappini F, Brigo M, et al. Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease. J Clin Endocrinol Metab 2015;100:401-6.
    1. Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol 2012;54:497-507.
    1. Llerena Junior JC, Nascimento OJ, Oliveira AS, et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease. Arq Neuropsiquiatr 2016;74:166-76.
    1. Schoser B, Laforet P, Kruijshaar ME, et al. 208th ENMC International Workshop: formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014. Neuromuscul Disord 2015;25:674-8.
    1. Tarnopolsky M, Katzberg H, Petrof BJ, et al. Pompe disease: diagnosis and management. Evidence-Based Guidelines from a Canadian Expert Panel. Can J Neurol Sci 2016;43:472-85.
    1. Bach JR. Respiratory considerations. Bach JR, ed. Guide to the evaluation and management of neuromuscular disease. Philadelphia: Hanley and Belfus; 1999, pp. 67-87.
    1. Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009;19:113-7.
    1. Vitacca M, Ambrosino N, Nava S, et al. Cure palliative dei pazienti con patologie respiratorie croniche avanzate non oncologiche. Position paper. Associazione Italiana Pneumologi Ospedalieri (AIPO). 2011. (Available from: . Accessed 5 February 2018).
    1. Vitacca M, Vianello A, Scientific Group on Respiratory Intensive Care of the Italian Association of Hospital P Respiratory outcomes of patients with amyotrophic lateral sclerosis: an Italian nationwide survey. Respir Care 2013;58:1433-41.
    1. Ambrosino N, Confalonieri M, Crescimanno G, et al. The role of respiratory management of Pompe disease. Respir Med 2013;107:1124-32.
    1. Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med 2009;103:477-84.
    1. Vitacca M, Grandi M, Sturani C, et al. Monitoring and care of neuromuscular and motoneuron diseases in respiratory setting: position paper by Sezione Regionale AIPO Lombardia. Rassegna di Patologia dell’Apparato Respiratorio 2009;24:64-9.
    1. Hill NS, Liesching T, Kwok H. Indications for non-invasive ventilation, Mechanical Ventilation. Slutsky AS, Brochard L, eds. Update in intensive care medicine. Berlin: Springer; 2004.
    1. Shneerson JM, Simonds AK. Noninvasive ventilation for chest wall and neuromuscular disorders. Eur Respir J 2002;20:480-7.
    1. Aslan GK, Huseyinsinoglu BE, Oflazer P, et al. Inspiratory muscle training in late-onset pompe disease: the effects on pulmonary function tests, quality of life, and sleep quality. Lung 2016;194:555-61.
    1. Jevnikar M, Kodric M, Cantarutti F, et al. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease. Mol Genet Metab Rep 2015;5:67-71.
    1. Jones HN, Crisp KD, Robey RR, et al. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): effects of training and detraining. Mol Genet Metab 2016;117:120-8.
    1. Hundsberger T, Rosler KM, Findling O. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol 2014;261:1684-90.
    1. van der Ploeg AT, Barohn R, Carlson L, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 2012;107:456-61.
    1. Vianello A, Semplicini C, Paladini L, et al. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung 2013;191:537-44.
    1. Bach JR, Saporito LR. Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure. A different approach to weaning. Chest 1996;110:1566-71.
    1. Baydur A, Adkins RH, Milic-Emili J. Lung mechanics in individuals with spinal cord injury: effects of injury level and posture. J Appl Physiol (Bethesda, Md : 1985) 2001;90:405-11.
    1. Mellies U, Ragette R, Schwake C, et al. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001;57:1290-5.
    1. Ragette R, Mellies U, Schwake C, et al. Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax 2002;57:724-8.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다